CoChat

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial

Caterson, I. D., Finer, N., Coutinho, W., Van Gaal, L. F., Maggioni, A. P., Torp‐Pedersen, C., Sharma, A. M., Legler, U. F., Shepherd, G. M., Rode, R. A., Perdok, R. J., Renz, C. L., James, W. P. T., on behalf of the SCOUT Investigators · 2012 · Diabetes, Obesity and Metabolism
Cited by 147

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aim: The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality. The relationship between 12‐month weight loss and subsequent cardiovascular outcomes is explored. Methods: Overweight/obese subjects (N = 10 744), ≥55 years with cardiovascular disease and/or type 2 diabetes mellitus, received sibutramine plus weight management during a 6‐week Lead‐in Period before randomization to continue sibutramine (N = 4906) or to receive placebo (N = 4898). The primary endpoint was the time from randomization to first occurrence of a primary outcome event (non‐fatal myocardial infarction, non‐fatal stroke, resuscitated cardiac arrest or cardiovascular death). Results: For the total population, mean weight change during Lead‐in Period (sibutramine) was −2.54 kg. Post‐randomization, mean total weight change to Month 12 was −4.18 kg (sibutramine) or −1.87 kg (placebo). Degree of weight loss during Lead‐in Period or through Month 12 was associated with a progressive reduction in risk for the total population in primary outcome events and cardiovascular mortality over the 5‐year assessment. Although more events occurred in the randomized sibutramine group, on an average, a modest weight loss of approximately 3 kg achieved in the Lead‐in Period appeared to offset this increased event rate. Moderate weight loss (3–10 kg) reduced cardiovascular deaths in those with severe, moderate or mild cardiovascular disease. Conclusions: Modest weight loss over short‐term (6 weeks) and longer‐term (6–12 months) periods is associated with reduction in subsequent cardiovascular mortality for the following 4–5 years even in those with pre‐existing cardiovascular disease. While the sibutramine group experienced more primary outcome events than the placebo group, greater weight loss reduced overall risk of these occurring in both groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01554.x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 147

Metadata

Authors
Caterson, I. D., Finer, N., Coutinho, W., Van Gaal, L. F., Maggioni, A. P., Torp‐Pedersen, C., Sharma, A. M., Legler, U. F., Shepherd, G. M., Rode, R. A., Perdok, R. J., Renz, C. L., James, W. P. T., & on behalf of the SCOUT Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-01-18
Volume
14
Issue
6
Pages
523-530
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1982950261
Cited by
147
References
11
FWCI
12.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01554.x
The paper
Caterson, I. D., Finer, N., Coutinho, W., Van Gaal, L. F., Maggioni, A. P., Torp‐Pedersen, C., Sharma, A. M., Legler, U. F., Shepherd, G. M., Rode, R. A., Perdok, R. J., Renz, C. L., James, W. P. T., & on behalf of the SCOUT Investigators. (2012). Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01554.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.